Cargando…

晚期肺癌患者免疫功能的系统评价及临床意义

BACKGROUND AND OBJECTIVE: The actual evaluation of immunological function is significant for studing the tumor development and devising a treatment in time. The aim of this study is to evaluate the immunological function of advanced lung cancer patients systematically, and to discuss the clinical si...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000421/
https://www.ncbi.nlm.nih.gov/pubmed/20677560
http://dx.doi.org/10.3779/j.issn.1009-3419.2010.04.12
_version_ 1783331719334592512
collection PubMed
description BACKGROUND AND OBJECTIVE: The actual evaluation of immunological function is significant for studing the tumor development and devising a treatment in time. The aim of this study is to evaluate the immunological function of advanced lung cancer patients systematically, and to discuss the clinical significance. METHODS: The nucleated cell amounts of advanced lung cancer patients and the healthy individuals were counted. The immune cell subsets and the levels of IL-4, INF-γ, perforin and granzyme in CD8(+)T cells by the flow cytometry were measured. The proliferation activity and the inhibition ratio of immune cells to several tumor cell lines were evaluated by MTT assay. RESULTS: The absolute amounts and subsets of T, B, NK cells of advanced lung cancer patients were lower than the healthy individuals (P < 0.05); However, the proportion of regulatory T cells of advanced lung cancer patients (4.00±1.84)% was lower than the healthy individuals (1.27±0.78)% (P < 0.05). The positive rates of IFN-γ perforin, granzyme in CD8(+)T cells decreased while them in IL-4 did not in the advanced lung cancer patients compared to the healthy control group (P < 0.05). The proliferation activity of immune cells, the positive rate of PPD masculine and the inhibition ratio to tumor cells in the advanced lung cancer patients was lower than the healthy subsets obviously (P < 0.05). CONCLUSION: There was a significant immune depression in the advanced lung cancer patients compared to the healthy individuals.
format Online
Article
Text
id pubmed-6000421
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60004212018-07-06 晚期肺癌患者免疫功能的系统评价及临床意义 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: The actual evaluation of immunological function is significant for studing the tumor development and devising a treatment in time. The aim of this study is to evaluate the immunological function of advanced lung cancer patients systematically, and to discuss the clinical significance. METHODS: The nucleated cell amounts of advanced lung cancer patients and the healthy individuals were counted. The immune cell subsets and the levels of IL-4, INF-γ, perforin and granzyme in CD8(+)T cells by the flow cytometry were measured. The proliferation activity and the inhibition ratio of immune cells to several tumor cell lines were evaluated by MTT assay. RESULTS: The absolute amounts and subsets of T, B, NK cells of advanced lung cancer patients were lower than the healthy individuals (P < 0.05); However, the proportion of regulatory T cells of advanced lung cancer patients (4.00±1.84)% was lower than the healthy individuals (1.27±0.78)% (P < 0.05). The positive rates of IFN-γ perforin, granzyme in CD8(+)T cells decreased while them in IL-4 did not in the advanced lung cancer patients compared to the healthy control group (P < 0.05). The proliferation activity of immune cells, the positive rate of PPD masculine and the inhibition ratio to tumor cells in the advanced lung cancer patients was lower than the healthy subsets obviously (P < 0.05). CONCLUSION: There was a significant immune depression in the advanced lung cancer patients compared to the healthy individuals. 中国肺癌杂志编辑部 2010-04-20 /pmc/articles/PMC6000421/ /pubmed/20677560 http://dx.doi.org/10.3779/j.issn.1009-3419.2010.04.12 Text en 版权所有©《中国肺癌杂志》编辑部2010 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床研究
晚期肺癌患者免疫功能的系统评价及临床意义
title 晚期肺癌患者免疫功能的系统评价及临床意义
title_full 晚期肺癌患者免疫功能的系统评价及临床意义
title_fullStr 晚期肺癌患者免疫功能的系统评价及临床意义
title_full_unstemmed 晚期肺癌患者免疫功能的系统评价及临床意义
title_short 晚期肺癌患者免疫功能的系统评价及临床意义
title_sort 晚期肺癌患者免疫功能的系统评价及临床意义
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000421/
https://www.ncbi.nlm.nih.gov/pubmed/20677560
http://dx.doi.org/10.3779/j.issn.1009-3419.2010.04.12
work_keys_str_mv AT wǎnqīfèiáihuànzhěmiǎnyìgōngnéngdexìtǒngpíngjiàjílínchuángyìyì
AT wǎnqīfèiáihuànzhěmiǎnyìgōngnéngdexìtǒngpíngjiàjílínchuángyìyì
AT wǎnqīfèiáihuànzhěmiǎnyìgōngnéngdexìtǒngpíngjiàjílínchuángyìyì
AT wǎnqīfèiáihuànzhěmiǎnyìgōngnéngdexìtǒngpíngjiàjílínchuángyìyì
AT wǎnqīfèiáihuànzhěmiǎnyìgōngnéngdexìtǒngpíngjiàjílínchuángyìyì
AT wǎnqīfèiáihuànzhěmiǎnyìgōngnéngdexìtǒngpíngjiàjílínchuángyìyì
AT wǎnqīfèiáihuànzhěmiǎnyìgōngnéngdexìtǒngpíngjiàjílínchuángyìyì
AT wǎnqīfèiáihuànzhěmiǎnyìgōngnéngdexìtǒngpíngjiàjílínchuángyìyì
AT wǎnqīfèiáihuànzhěmiǎnyìgōngnéngdexìtǒngpíngjiàjílínchuángyìyì
AT wǎnqīfèiáihuànzhěmiǎnyìgōngnéngdexìtǒngpíngjiàjílínchuángyìyì
AT wǎnqīfèiáihuànzhěmiǎnyìgōngnéngdexìtǒngpíngjiàjílínchuángyìyì
AT wǎnqīfèiáihuànzhěmiǎnyìgōngnéngdexìtǒngpíngjiàjílínchuángyìyì
AT wǎnqīfèiáihuànzhěmiǎnyìgōngnéngdexìtǒngpíngjiàjílínchuángyìyì